Type 1 Diabetes Trial, Recruiting NCT04200391 Sponsor: Boston Children's Hospital Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT04200391
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had Type 1 diabetes for at least 1 year
  • People aged 18 to 40 years
  • People who have reached at least Tanner stage IV of physical maturity (a measure of physical development — confirm with trial site if unsure)
  • People with a body mass index (BMI) between 18.5 and 35
  • People whose blood sugar levels have been reasonably stable, shown by an HbA1c (a 3-month blood sugar average) between 6.5% and 9%
  • People who currently use a continuous glucose monitor (CGM) — a device that tracks blood sugar levels throughout the day
  • People who currently use an insulin pump to manage their diabetes
  • People who have attended at least one diabetes care appointment in the past 12 months, including virtual visits

Who may not be able to join:

  • People who have had diabetic ketoacidosis (a serious diabetes complication) or a severe low blood sugar episode involving a seizure or loss of consciousness in the past 6 months
  • People with dietary restrictions or food intolerances — such as coeliac disease, a stomach condition called gastroparesis, or certain food allergies — that would be incompatible with the meals provided as part of the trial
  • People who are currently following a weight-loss diet or any other type of restrictive eating plan
  • People who do vigorous exercise for more than 2 hours on more than 3 days per week
  • People who have a history of an eating disorder, or who are considered at risk of one based on a standard screening tool called the Eating Disorders Diagnostic Scale (EDDS)
  • People who have a major medical condition, or who take medications other than insulin and metformin, that could affect blood sugar or metabolism
  • People with a significant mental health condition
  • People who smoke, use recreational drugs, or drink alcohol heavily
  • People who are pregnant or breastfeeding
  • People who have anaemia (low red blood cell levels)
  • For participants who take part in MRI scans, additional criteria apply, including:
    • Standard reasons that would make an MRI unsafe (such as having certain metal implants — confirm with trial site)
    • Irregular menstrual cycles
    • Use of certain psychiatric medications, unless those medications can safely be paused for several days around the MRI, or unless they are mild antidepressants or anti-anxiety medications considered acceptable by the trial site

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Belinda S Lennerz, Boston Children's Hospital

Phone: 8572183896

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Boston Children's Hospital
Registry
ClinicalTrials.gov
Start date
3 January 2020
Est. completion
31 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Glucagon treatment success, defined as an increase in glucose level to ≥ 70 mg/dL or an Increase of ≥ 20 mg/dL from glucose nadir within 30 minutes after receiving 1 mg glucagon IM

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov